公司资料
Enlivex Therapeutics 股价、新闻与催化剂
- 股票代码:
- ENLV
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Israel and listed in the U
股票表现
1.27 USD (-8.63%)
收盘价
最后更新: 2026年11月5日
205M USD
市值
股价为何变动
截至 2026年11月5日，ENLV 下跌 8.63%，收于 $1.27。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.
所在地与行业分类
Enlivex is headquartered in Israel and listed in the U.S. market. It sits in small-cap immunology biotechnology.
商业模式特征
The company depends on translational validation, early clinical progress, and capital support. Investors typically watch proof-of-concept data and whether the platform can create durable value.
生物医药行业定位
Enlivex occupies a niche innate-immunity position within biotech. The stock is driven by whether macrophage reprogramming can become a meaningful therapeutic strategy.
未来催化剂
- Enlivex’s catalysts are Allocetra and its osteoarthritis / immunology programs, along with any update that clarifies whether the platform still has a viable path. The company remains data-sensitive.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。